IL6 and triple-negative breast carcinoma: Similarly, in atezolizumab-treated patients with metastatic triple-negative breast cancer (TNBC) from the PCD4989g clinical trial,13 or with metastatic urothelial bladder carcinoma (UC) from the IMvigor210 and IMvigor211 trials,14,15,16 plasma IL-6 was elevated compared with healthy controls (Figure S1B) and associated with poor OS in multivariate survival analysis (Figures S1G–S1I).